JPH0827033A - Erythritol-containing solid agent - Google Patents

Erythritol-containing solid agent

Info

Publication number
JPH0827033A
JPH0827033A JP18414894A JP18414894A JPH0827033A JP H0827033 A JPH0827033 A JP H0827033A JP 18414894 A JP18414894 A JP 18414894A JP 18414894 A JP18414894 A JP 18414894A JP H0827033 A JPH0827033 A JP H0827033A
Authority
JP
Grant status
Application
Patent type
Prior art keywords
erythritol
property
solid
contains
alcohol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP18414894A
Other languages
Japanese (ja)
Inventor
Isamu Masuyama
勇 増山
Original Assignee
Nikken Chem Co Ltd
日研化学株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Abstract

PURPOSE:To obtain a solid agent such as a tablet or a capsule by uniformly blending an erythritol having properties such as sweetness, fine powder-forming property, low hygroscopic property and stability as an additive for medicine such as a vehicle or a damp proof material with a pharmacodynamic ingredient. CONSTITUTION:This solid agent contains a pharmacodynamic ingredient and erythritol in a homogeneous state and contains preferably 1-99wt.% of erythritol. Furthermore, erythritol is quadrivalent sugar alcohol and is used as a sweetener having ultra-low energy and has crystals or powder with 122 molecular weight and 119 deg.C melting point and soluble in water and has good-quality sweetness and hardly cause diarrhea compared with other sugar alcohol and has noncariogenic property and does not cause browning reaction with amino acids or protein-based medicines. Erythritol exists in fruits, lichens, mushrooms, etc. An example of a preparation using the solid gent is to mix theophylline of 1kg with erythritol of 2.5kg, crystalline cellulose of 0.5kg and calcium stearate of 0.02kg, grind the mixture and form into tablets so as to become 200mg per tablet.

Description

【発明の詳細な説明】 DETAILED DESCRIPTION OF THE INVENTION

【0001】 [0001]

【産業上の利用分野】本発明は、エリスリトールを賦形剤、防湿剤、安定化剤、等の医薬品添加物として用いてなる、錠剤、カプセル剤、丸剤、顆粒剤、散剤、トローチ剤、エキス剤などの固形剤に関する。 BACKGROUND OF THE INVENTION This invention, excipients erythritol, moisture, stabilizers, comprising using as excipients etc., tablets, capsules, pills, granules, powders, troches, on the solid agent such as extract agent.

【0002】 [0002]

【従来の技術】一般的に経口医薬品は、投与後消化器官に到達して溶解後吸収され、生体内に分布して薬効が発揮されるものである。 BACKGROUND ART Generally, an oral medicine is absorbed after dissolution reached the administration after digestion organs, distributed in a living body in which efficacy is exhibited. 経口投与のために、錠剤、カプセル剤、散剤、顆粒剤、トローチ剤等の固形剤が考え出され、これら固形剤を作成したり、機能性を高める目的で、多種多様の医薬品添加物が開発されてきている。 For oral administration, tablets, capsules, powders, granules, solid preparations such as lozenges conceived, to create these solid agent in order to enhance the functionality, developed a wide variety of pharmaceutical additives it has been. 錠剤、顆粒剤などの固形剤の製造には、従来から多種類の添加剤がその目的に応じて用いられている。 Tablets, the preparation of a solid agent such as granules, various kinds of additives conventionally used depending on the purpose. これらの添加剤は、有効量が少ない薬物や打錠など製剤化に適しない薬物の増量や賦形性を目的としたり、塩酸チアミンなどの様な吸湿性の高い薬物の防湿化や安定化を目的としたり、イブプロフェン、シメチジン、テオフィリン、キニーネなどの様な苦みを有している薬物や、コレスチラミンなどの様に臭いを有する薬剤の、矯味、矯臭などの目的で広く使用されている。 These additives, or for the purpose of increasing and shaping of the effective amount is not appropriate, such as in the formulation less drug and tableting drug, the moisture reduction and stabilization of such highly hygroscopic drugs such as thiamine hydrochloride or the purpose, ibuprofen, cimetidine, theophylline, and drugs having a bitter, such as such as quinine, an agent having odor as such cholestyramine, flavoring, are widely used for purposes such as flavoring.

【0003】これらの添加剤のうち、白糖、果糖、ブドウ糖、乳糖、マルトース、デキストリンなどの糖類の添加剤が、化学合成品とは違い安全性での問題点が殆どなく、結晶や粉末で取扱い易く、しかも安価であるため、 [0003] Among these additives, white sugar, fructose, glucose, lactose, maltose, sugar additives such as dextrin, problems hardly in differences safety and chemically synthesized products, handling crystalline or powder easy, yet because it is inexpensive,
頻繁に使用されている。 It is frequently used. しかしながらこれらの糖類はそれ自体吸湿性があったり、アミノ酸、タンパク質系の薬物との共存下で、酸、アルカリ、熱により着色や成分の変化を起こすなどの問題点を有している。 However, these saccharides or have itself hygroscopic, amino acids, in the presence of a drug of protein-based, have acid, alkali, problems such as causing changes in coloring and components by heat. さらに、う蝕原性があり、しかもカロリーが高い等、健康上からも好ましくないなど、使用に制限を受けざるを得ない。 In addition, there are cariogenic, yet high in calories, etc., such as undesirable from the health, forced to not subject to restrictions on use.

【0004】糖類に代わる添加剤として、グリセリン、 [0004] as an additive to replace the sugar, glycerin,
ソルビトール、キシリトール、マルチトール、マンニトールなどの糖アルコールがある。 Sorbitol, xylitol, maltitol, a sugar alcohol such as mannitol. これらの糖アルコールは還元基を持たないので、アミノ酸やタンパク質系の薬剤と通常褐変を起こす心配はなく、またう蝕原性もない。 Because these sugar alcohol does not have a reducing group, rather than worry about causing a drug and usually browning of the amino acid and protein-based, Matau 蝕原 of no. しかし、ソルビトールやマルチトールなどの糖アルコールは褐変は起こしにくいが、ショ糖等に比べて吸湿性が高いという問題点がある。 However, sugar alcohols such as sorbitol and maltitol browning is difficult to cause, but there is a problem that the high hygroscopicity as compared with sucrose and the like. 吸湿性が高いと微粉末での機械適性に問題が残り、また錠剤など製剤の保存性にも影響を与えるなどの、好ましくない問題点をかかえている。 Remainder is highly hygroscopic problems machinability in the fine powder, also including also affects the storage stability of the formulation such as tablets, suffer from undesirable problems. また、グリセリンは液状であるため、固形剤の製造には適さない。 Further, glycerin because it is liquid, not suitable for the manufacture of solid dosage. さらに、これらの糖アルコールは摂取しすぎると下痢を起こし易く、使用の制限を受けざるを得ない。 Furthermore, susceptible to these sugar alcohols diarrhea too ingested forced to undergo the use restrictions. 吸湿性が低い糖アルコールとして唯一マンニトールがあり、極めて低い吸湿性が示されている。 The only mannitol there as a hygroscopic low sugar alcohols, have very low moisture absorption is shown. しかし、マンニトールは水への溶解性が低すぎる上、価格が高いという欠点を有する。 However, mannitol on solubility in water is too low, with the disadvantage of high price.

【0005】従来、エリスリトールを薬剤に使用した例としては、固形薬剤の表面にメソ-エリスリトール(エリスリトール)を主成分とする被覆材の被覆層を形成せしめてなる被覆固形薬剤(特開平1−268628)及び薬剤成分をエリスリトールの結晶及び/又はしゅう晶間に含有せしめてなる薬剤成分固定化組成物(特開平1 [0005] As a conventional example using erythritol agent, meso on the surface of the solid agent - erythritol comprising brought forming a coating layer of coating material mainly composed of (erythritol) coated solid agent (JP-A 1-268628 ) and pharmaceutical ingredient of erythritol crystals and / or pharmaceutical ingredients immobilization composition comprising the additional inclusion in the week interdendritic (JP-1
−268627)が知られている。 -268,627) have been known. しかしながら、今まで、薬物とエリスリトールの結晶又は粉末を均一に混合した後、錠剤等の固形剤にした例は知られていない。 However, until now, it was uniformly mixed crystals or powder drug and erythritol, example of a solid agent such as tablets is not known.

【0006】 [0006]

【発明が解決しようとする課題】本発明は、アミノ酸やタンパク質系の薬物と褐変を起こさず、吸湿性の低い微粉末の形態になり易く、下痢を起こし難く、適度な水溶性を併せ持ち、且つ非う蝕原性と低カロリー性を保有する、医薬品添加物を見い出すことである。 [SUMMARY OF THE INVENTION The present invention, without causing drug and browning of an amino acid and protein-based, tends to become less fine powder form of hygroscopic hardly cause diarrhea, it combines the proper water solubility and carrying non cariogenic and low calorie, it is to find a pharmaceutical additive.

【0007】 [0007]

【課題を解決するための手段】本発明者は、鋭意研究の結果、これらの性質、特徴を併せ持つ素材として、エリスリトールを見い出すに至った。 Means for Solving the Problems The present inventors have, as a result of intense research, these properties, as a material that combines the features, and have found erythritol. エリスリトールは皮膜形成性、微粉末形成性、低吸湿性及び易結晶性等の性質を併せ持ち、適度の溶解性を持っている。 Erythritol combines film-forming, powder forming, properties such as low hygroscopicity and easily crystallizable, has moderate solubility. この様な性質は、固形剤を製造する際の、賦形剤、防湿剤、安定化剤、糖衣剤などの医薬品添加物としての機能を十分に持ち合わせており、特に微粉末形成のし易さ、及び低い吸湿性は、既に医薬品添加物として使用されている他の糖や糖アルコール類を凌ぐものである。 Such properties are in the production of solid, excipients, desiccants, stabilizers, and ready sufficiently function as a pharmaceutical additives such as dragees, especially finely powdered form easiness , and low hygroscopicity are those already surpass other sugars and sugar alcohols which are used as pharmaceutical additives. すなわち、本発明は、薬効成分とエリスリトールを均一に含有してなる固形剤であり、更に詳しくは、固形剤中に薬効成分及び1 That is, the present invention is a solid dosage formed by uniformly containing medicinal ingredient and erythritol, more particularly, medicinal ingredient and 1 in a solid dosage
ー99重量%、好ましくは5−95重量%のエリスリトールを均一に含有してなる固形剤である。 Over 99 wt%, a solid agent preferably comprising a uniform erythritol 5-95 wt%. 本発明の固形剤は、従来から使用されている糖類又は糖アルコールの代わりに或はその一部としてエリスリトールを用いて常法により製造される。 Solid forms of the present invention, using erythritol is prepared in a conventional manner as the or part instead of sugars or sugar alcohols are conventionally employed. この際、医薬品添加物としてエリスリトールだけを使用してもよいが、一般には、他の賦形剤や防湿剤、安定剤と併用されることが多い。 At this time, it may be used only erythritol as a pharmaceutical additive, but generally, other excipients and desiccant are often used in combination with stabilizers.

【0008】本発明におけるエリスリトールとは、4価の糖アルコールで、近年、食品市場を中心に出回り始めた超低エネルギー甘味料であり、分子量122、融点1 [0008] The erythritol in the present invention is a tetravalent sugar alcohols, in recent years, an ultra low energy sweetener was forged around the food market, molecular weight 122, melting point 1
19℃の結晶あるいは粉末で、水に溶解し、質の良い甘味性を有し、ソルビトールなど他の糖アルコールと比較して下痢を起こし難く、非う蝕原性であり、アミノ酸、 At 19 ° C. of crystals or powder, soluble in water, it has a good sweetness quality, hardly cause diarrhea as compared to other sugar alcohols such as sorbitol, a non-cariogenic, amino acids,
タンパク質系の薬剤と褐変反応を起こさない糖質系の素材である。 It does not cause drug and browning reaction of the protein system is a material saccharide. エリスリトールは天然界に、梨、ブドウ、スイカ、メロンなどの果実類をはじめとして、地衣類、キノコ類などに存在し、ワイン、清酒、醤油などの発酵食品にも含まれており、これまでにも食品として食経験がある、極めて安全性の高い素材である。 Erythritol in nature, pears, grapes, watermelon, including the fruit such as melon, lichens, exist in such as mushrooms, wine, sake, is also included in fermented foods such as soy sauce, so far there is a food experience as well as food, is a highly safe material.

【0009】エリスリトールは経口で摂取された場合、 [0009] When erythritol, which is taken orally,
大部分が小腸から吸収され、全く代謝を受けずに速やかに尿中に排泄されること、及び一部未吸収のものだけが大腸に達し、腸内菌による発酵を受けて短鎖脂肪酸になり、これが大腸から吸収されてエネルギー源になることが知られている。 Largely absorbed from the small intestine, it is excreted rapidly in the urine without being completely metabolized, and only the part unabsorbed reaches the large intestine, it receives the fermentation by intestinal bacteria to the short-chain fatty acids This is known to be absorbed from the large intestine becomes an energy source. エリスリトールはソルビトールなどと同じ糖アルコールの一種であるが、他の糖アルコールと違い小腸から良く吸収されるので、大腸に達する量が少なく、浸透圧性の下痢が起き難い。 Although erythritol is a kind of the same sugar alcohol such as sorbitol, since it is well absorbed from the small intestine unlike other sugar alcohols, small amounts reaching the large intestine, osmotic diarrhea hardly occur. 下痢の起こり易さは、通常ソルビトールの 1/3〜1/4であると考えられている。 Likelihood of occurrence of diarrhea, is believed to be 1 / 3-1 / 4 the normal sorbitol. これに反してソルビトール等の他の糖アルコールは、小腸では殆ど吸収されずに、そのまま大腸に達するので、浸透圧性の下痢を起こし易く、さらに大腸で発酵を受ける量も多いので、その分エネルギー値は高くならざるを得ない。 Other sugar alcohols such as sorbitol Contrary to this, with little absorption in the small intestine, so it reaches the large intestine, susceptible to osmotic diarrhea, since more amount often undergo fermentation in the large intestine, correspondingly energy value inevitably high. 一方小腸で吸収されたエリスリトールは、生体で全く代謝を受けずにそのまま尿中に排泄されるため、全くエネルギーにならず、ごく僅かに大腸で発酵された分だけがエネルギーになるため、有効エネルギー値は極めて低く、0.3kcal/g以下と報告されている。 Erythritol Meanwhile absorbed in the small intestine, because it is excreted unchanged in the urine without being completely metabolized in vivo, not at all in energy, since the amount corresponding fermented in very slightly large intestine is energy, useful energy the value is very low, it has been reported that following 0.3kcal / g.
(食品化学新聞社発行、別冊フードケミカル−4、甘味料総覧、p.188−194) エリスリトールは物理的、化学的に安定であるばかりでなく、上記の如く生体に投与されたエリスリトールは殆ど利用されずに体外に排泄され、しかもこの際生体に全く悪影響を及ぼさないので、生体に影響を及ぼさないことが求められる医薬品添加物として、非常に好ましい。 (Food Chemistry newspaper issue, separate hood Chemical -4 sweeteners overview, P.188-194) erythritol physically, not only chemically stable, erythritol administered to living body as described above is most available are excreted without being, moreover does not adversely entirely negative effect on the time biological, as pharmaceutical additives required to have no effect on the biological, highly preferred.

【0010】エリスリトールは極めて吸湿性の低い微粉末になるため、主薬である医薬品粉末との混合性に優れており、錠剤、散剤、丸剤、顆粒剤、トローチ剤、エキス剤などの固形剤を製造する際の賦形剤や、防湿剤、安定剤として最適である。 [0010] Since erythritol be extremely hygroscopic low fine powder, it is excellent in mixing property with a pharmaceutical powder as a principal agent, tablets, powders, pills, granules, lozenges, solid agent such as extract agent and excipients in the manufacture, the optimum moisture agent, as a stabilizer. とりわけ錠剤製造における打錠の際の機械適性が良好であり、賦形剤として優れた効果を発揮する。 Especially the machinability at the time of tabletting in tablet production is good, and an excellent effect as an excipient. 試験例1に示す通り、エリスリトールを賦形剤として製造した錠剤は非常に吸湿性が低く、安定性に優れている。 As shown in Test Example 1, tablets prepared erythritol as an excipient is very low hygroscopicity and excellent in stability.

【0011】 [0011]

【実施例】以下に、実施例、参考例、試験例をあげてさらに詳細に説明するが、本発明はこれらの例により限定を受けるものではない。 EXAMPLES Hereinafter, examples, reference examples, described in more detail by way of Test Examples, the present invention is not intended to be limited to these examples. 実施例1 テオフィリン1kg、エリスリトール2.5kg、結晶セルロース0.5kg、ステアリン酸カルシウム0.02 kgを加え、混合機内で5分間混合粉砕した後、打錠機を用いて1錠200m Example 1 Theophylline 1 kg, erythritol 2.5 kg, crystalline cellulose 0.5 kg, calcium stearate 0.02 kg was added and mixed and ground for 5 minutes in a mixing machine, one tablet 200m using a tablet machine
gに打錠して錠剤を製造した。 Tablets were prepared and compressed into g. 参考例1(対照製剤の製造) エリスリトールの代わりにマルチトールを用い実施例1 Reference Example 1 using maltitol instead of (control preparation of the formulation) erythritol Example 1
と同様にして錠剤を製造した。 Tablets were prepared in the same manner as.

【0012】実施例2 バルプロ酸ナトリウム1600gとエリスリトール2000g及びアラビアガム160gを充分混合した後、5%ヒドロキシプロピルセルロースのエタノール溶液650gを加えて練合する。 [0012] After thoroughly mixing the Example 2 Sodium valproate 1600g and erythritol 2000g and gum arabic 160 g, it is kneaded by adding an ethanol solution 650g of 5% hydroxypropyl cellulose. この練合物を60℃の熱風乾燥機にて乾燥後、1000μ After drying the kneaded product at 60 ° C. in a hot air dryer, 1000 [mu]
mのふるいにより整粒して顆粒剤を製造した。 Was prepared granules are sieved through a sieve of m. 実施例3 実施例2で製造した顆粒剤を、ゼラチンカプセルに充填してカプセル剤を製造した。 The granules prepared in Example 3 Example 2 was prepared capsules was filled in a gelatin capsule.

【0013】実施例4 エリスリトール920gとアラビアガム70gに、アズレンスルホン酸ナトリウム10gを加えて混合機にて充分に混合した後、打錠機を用いて圧縮成形してトローチ剤を製造した。 [0013] Example 4 Erythritol 920g gum arabic 70 g, was mixed thoroughly in a mixer by adding sodium azulene sulfonate 10 g, was prepared lozenges by compression molding using a tablet machine. 本トローチ剤は冷感とさわやかな甘味を持ち、優れた服用感が得られた。 This lozenge has a refreshing sweetness and Hiyakan, obtained excellent ingestion feel. 実施例5 リン酸ジヒドロコデイン50gにエリスリトール4950gを加え、混合機にて均一によく混和した後、500μmのふるいを通過させて散剤を製造した。 Erythritol 4950g added to Example 5 phosphate dihydrocodeine 50 g, was uniformly mixed well with a mixer, to produce a powder passed through a 500μm sieve.

【0014】実施例6 塩酸キニーネ400gにエリスリトール600g及びヒドロキシプロピルセルロース50gを添加して充分に混合した後、 [0014] After thorough mixing with the addition of erythritol 600g and hydroxypropyl cellulose 50g Example 6 quinine hydrochloride 400 g,
成丸器を使用して丸剤を製造した。 It was prepared pills using Narumaru device. 実施例7 ロートコン粗末 200g を 35%エタノールを浸出剤として、パーコレーション法に準じて浸出する。 EXAMPLE 7 Rotokon poor 200g as lixiviant 35% ethanol, leached in accordance with percolation method. 浸出液を減圧下に濃縮した後、エリスリトール200gを添加して良く混合し、50℃の温風で乾燥して、乾燥エキス剤を製造した。 After concentration of the leaching solution under reduced pressure, mixed well with the addition of erythritol 200 g, was dried at 50 ° C. hot air, to produce a dry extract agent.

【0015】試験例1 実施例1及び参考例1で製造した錠剤を室温中で相対湿度85%の条件下に7日間保存して、吸湿による重量変化を測定した。 [0015] The tablets prepared in Test Example 1 Example 1 and Reference Example 1 was stored for 7 days under a relative humidity of 85% at room temperature and weighed change due to moisture absorption. その結果、エリスリトールを使用した錠剤の重量変化(吸湿率)は0.15%であり極めて吸湿性が低かった。 As a result, the weight change (moisture absorption rate) of the tablets using erythritol was less highly hygroscopic 0.15%. 一方、対照製剤であるマルチトールを使用した錠剤の増加率は6.8%であった。 On the other hand, the increase rate of the tablets using maltitol in contrast formulation was 6.8%.

【0016】 [0016]

【発明の効果】エリスリトールが有する、爽やかな甘味性、微粉末形成性の良さ、低吸湿性、安定性の良さ等の性質により、本発明にかかる固形剤は、ほとんど吸湿せず非常に安定でかつ服用し易い。 Erythritol has, according to the present invention, refreshing sweetness, fine powders formed of good, low moisture absorption, the nature of such good stability, solid dosage according to the present invention is very stable with little moisture absorption and easy to take. 更に、本発明にかかるエリスリトールは、打錠、圧縮等の機械適性に優れているため錠剤等の製造が容易である。 Furthermore, erythritol according to the present invention is easy to manufacture such as tablets because of its excellent tabletting, machinability such as compression.

Claims (2)

    【特許請求の範囲】 [The claims]
  1. 【請求項1】薬効成分とエリスリトールを均一に含有してなる固形剤。 1. A medicinal ingredient and a solid agent comprising uniformly erythritol.
  2. 【請求項2】固形剤中にエリスリトールを1ー99重量%含有してなる請求項1記載の固形剤。 2. A solid preparation according to claim 1, wherein comprising 1 over 99% by weight of erythritol in the solid agent.
JP18414894A 1994-07-14 1994-07-14 Erythritol-containing solid agent Pending JPH0827033A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP18414894A JPH0827033A (en) 1994-07-14 1994-07-14 Erythritol-containing solid agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP18414894A JPH0827033A (en) 1994-07-14 1994-07-14 Erythritol-containing solid agent

Publications (1)

Publication Number Publication Date
JPH0827033A true true JPH0827033A (en) 1996-01-30

Family

ID=16148212

Family Applications (1)

Application Number Title Priority Date Filing Date
JP18414894A Pending JPH0827033A (en) 1994-07-14 1994-07-14 Erythritol-containing solid agent

Country Status (1)

Country Link
JP (1) JPH0827033A (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0839526A2 (en) * 1996-10-31 1998-05-06 Takeda Chemical Industries, Ltd. Solid pharmaceutical preparation with fast buccal disintegration or dissolution
EP0922464A4 (en) * 1996-07-12 2000-07-05 Daiichi Seiyaku Co Quickly disintegrable compression-molded materials and process for producing the same
US7070805B2 (en) 1998-07-28 2006-07-04 Takeda Pharmaceutical Company Limited Rapidly disintegrable solid preparation
EP1736144A2 (en) 1998-05-18 2006-12-27 Takeda Pharmaceutical Company Limited Orally disintegrable tablets
JP2007119453A (en) * 2005-09-29 2007-05-17 Daiichi Sankyo Healthcare Co Ltd Method for preventing lowering of bromhexine hydrochloride content
WO2007097325A1 (en) * 2006-02-20 2007-08-30 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition comprising oseltamivir phosphate
JP2007525534A (en) * 2004-03-01 2007-09-06 ブリタニア ファーマシューティカルズ リミテッド The powder composition of sensitive active substances in the state of at least partially amorphous
EP1944017A2 (en) 2007-01-11 2008-07-16 Tedec-Meiji Farma, S.A. Rapidly disintegrating tablet in the oral cavity
JP2008271829A (en) * 2007-04-27 2008-11-13 Mitsubishi Shoji Foodtech Co Ltd Directly tabletable granule and tableted product
WO2010018866A1 (en) * 2008-08-14 2010-02-18 杏林製薬株式会社 Stabilized pharmaceutical composition

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0922464A4 (en) * 1996-07-12 2000-07-05 Daiichi Seiyaku Co Quickly disintegrable compression-molded materials and process for producing the same
EP1380308A1 (en) * 1996-07-12 2004-01-14 Daiichi Pharmaceutical Co., Ltd. Quickly disintegrable compression-molded materials and process for producing the same
EP0839526A2 (en) * 1996-10-31 1998-05-06 Takeda Chemical Industries, Ltd. Solid pharmaceutical preparation with fast buccal disintegration or dissolution
EP0839526A3 (en) * 1996-10-31 1999-01-07 Takeda Chemical Industries, Ltd. Solid pharmaceutical preparation with fast buccal disintegration or dissolution
US7875292B2 (en) 1998-05-18 2011-01-25 Takeda Pharmaceutical Company Limited Orally disintegrable tablets
EP1736144A2 (en) 1998-05-18 2006-12-27 Takeda Pharmaceutical Company Limited Orally disintegrable tablets
EP2263660A2 (en) 1998-05-18 2010-12-22 Takeda Pharmaceutical Company Limited Orally disintegrable tablets
US7431942B2 (en) 1998-05-18 2008-10-07 Takeda Pharmaceutical Company Limited Orally disintegrable tablets
US9901546B2 (en) 1998-05-18 2018-02-27 Takeda Pharmaceutical Company Limited Orally disintegrable tablets
US7070805B2 (en) 1998-07-28 2006-07-04 Takeda Pharmaceutical Company Limited Rapidly disintegrable solid preparation
JP2007525534A (en) * 2004-03-01 2007-09-06 ブリタニア ファーマシューティカルズ リミテッド The powder composition of sensitive active substances in the state of at least partially amorphous
JP2007119453A (en) * 2005-09-29 2007-05-17 Daiichi Sankyo Healthcare Co Ltd Method for preventing lowering of bromhexine hydrochloride content
WO2007097325A1 (en) * 2006-02-20 2007-08-30 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition comprising oseltamivir phosphate
JP5255429B2 (en) * 2006-02-20 2013-08-07 中外製薬株式会社 Oseltamivir phosphate containing pharmaceutical composition
US9012499B2 (en) 2006-02-20 2015-04-21 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition comprising oseltamivir phosphate
EP1944017A2 (en) 2007-01-11 2008-07-16 Tedec-Meiji Farma, S.A. Rapidly disintegrating tablet in the oral cavity
EP1944017A3 (en) * 2007-01-11 2012-07-18 Tedec-Meiji Farma, S.A. Rapidly disintegrating tablet in the oral cavity
JP2008271829A (en) * 2007-04-27 2008-11-13 Mitsubishi Shoji Foodtech Co Ltd Directly tabletable granule and tableted product
JPWO2010018866A1 (en) * 2008-08-14 2012-01-26 杏林製薬株式会社 Stabilized pharmaceutical composition
WO2010018866A1 (en) * 2008-08-14 2010-02-18 杏林製薬株式会社 Stabilized pharmaceutical composition

Similar Documents

Publication Publication Date Title
US3138525A (en) Castor wax-amprotropine-resin compositions
US5958455A (en) Oral solid dosage forms, methods of making same and compositions thereof
US4017598A (en) Preparation of readily disintegrable tablets
US5169639A (en) Controlled release verapamil tablets
US5621005A (en) Aqueous pharmaceutical suspension for substantially water insoluble pharmaceutical actives
US5505959A (en) Pharmaceutical composition in gel form in a dispensing package
US6060078A (en) Chewable tablet and process for preparation thereof
US3873694A (en) Direct compression tabletting composition and pharmaceutical tablets produced therefrom
US5204115A (en) Directly compressible xylitol and method
US6447807B1 (en) Potassium (-)-hydroxycitric acid methods for pharmaceutical preparations for stable and controlled delivery
EP0361680B1 (en) Morphine-containing composition
US4859704A (en) Water soluble ibuprofen compositions and methods of making them
US4950689A (en) Pectin delivery system
US5211958A (en) Pharmaceutical composition and process for its preparation
US5312626A (en) Lozenge or chewable tablet
US4605666A (en) Process for preparing spray-dried powders containing a water-soluble vitamin and powders prepared thereby
US4880830A (en) Slow release formulation
US5536526A (en) Xylitol-based binding and diluting agent and a process for the production thereof
US4956386A (en) Pharmaceutical compositions and process for their preparation
US20030099690A1 (en) Rapidly soluble film preparation
US4013775A (en) Process for preparing a sugar tablet
US6187336B1 (en) Process for producing a solid which is rapidly soluble in the oral cavity
US20030161888A1 (en) Pharmaceutical Composition
US4835186A (en) Spray dried ibuprofen
EP0282020A2 (en) Pharmaceutical preparations containing non-steroidal anti-inflammatory agents